US equities |
NVDA $239.99 ▲+2.58% SPCX $169.45 ▲+6.60% MU $1,063.33 ▼-1.08% TSLA $379.80 ▲+2.49% SNDK $1,706.09 ▼-0.81% MSFT $528.79 ▲+2.18% INTC $116.11 ▼-2.70% META $743.03 ▲+2.05%
FinancialContent

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.850 +0.040 (+0.83%)
Delayed Quote Updated: 3:38 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study ↗
Coya Therapeutics reports mixed data from Phase 2 study of low-dose IL-2 in Alzheimer's, showing safety and potential cognitive benefits in q4wks regimen. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces $10.0 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present at Upcoming Healthcare Conferences
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
7 Biotech Stocks to Put on Your Breakthrough Radar ↗
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
News headline image
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases ↗
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,... 
Via Benzinga
News headline image
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024 ↗
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >